What is a stock summary page? Click here for an overview.
Business Description
CytoSorbents Corp
NAICS : 621511
SIC : 3841
ISIN : US23283X2062
Description
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.12 | |||||
| Equity-to-Asset | 0.23 | |||||
| Debt-to-Equity | 2.42 | |||||
| Debt-to-EBITDA | -1.56 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -8.26 | |||||
| Beneish M-Score | -2.55 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -10.8 | |||||
| 3-Year EBITDA Growth Rate | 10.6 | |||||
| 3-Year EPS without NRI Growth Rate | 23.3 | |||||
| 3-Year FCF Growth Rate | 13 | |||||
| 3-Year Book Growth Rate | -47.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 51.91 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 22.13 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 58.58 | |||||
| 9-Day RSI | 59.77 | |||||
| 14-Day RSI | 57.38 | |||||
| 6-1 Month Momentum % | 0.5 | |||||
| 12-1 Month Momentum % | 29.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.2 | |||||
| Quick Ratio | 1.92 | |||||
| Cash Ratio | 0.33 | |||||
| Days Inventory | 121.42 | |||||
| Days Sales Outstanding | 70.96 | |||||
| Days Payable | 104.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.9 | |||||
| Shareholder Yield % | -9.49 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 70.59 | |||||
| Operating Margin % | -47.16 | |||||
| Net Margin % | -58.21 | |||||
| FCF Margin % | -42.41 | |||||
| ROE % | -124.44 | |||||
| ROA % | -41.67 | |||||
| ROIC % | -46.2 | |||||
| 3-Year ROIIC % | 81.52 | |||||
| ROC (Joel Greenblatt) % | -77.51 | |||||
| ROCE % | -49.44 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.74 | |||||
| PB Ratio | 5.71 | |||||
| Price-to-Tangible-Book | 8.79 | |||||
| EV-to-EBIT | -4.9 | |||||
| EV-to-Forward-EBIT | -7.27 | |||||
| EV-to-EBITDA | -5.39 | |||||
| EV-to-Forward-EBITDA | -8.29 | |||||
| EV-to-Revenue | 2.62 | |||||
| EV-to-Forward-Revenue | 2.32 | |||||
| EV-to-FCF | -6.13 | |||||
| Price-to-GF-Value | 0.77 | |||||
| Price-to-Median-PS-Value | 0.18 | |||||
| Earnings Yield (Greenblatt) % | -20.41 | |||||
| FCF Yield % | -21.11 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CTSO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CytoSorbents Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 35.595 | ||
| EPS (TTM) ($) | -0.379 | ||
| Beta | 1.7 | ||
| 3-Year Sharpe Ratio | -0.06 | ||
| 3-Year Sortino Ratio | -0.1 | ||
| Volatility % | 98.76 | ||
| 14-Day RSI | 57.38 | ||
| 14-Day ATR ($) | 0.076106 | ||
| 20-Day SMA ($) | 1.016625 | ||
| 12-1 Month Momentum % | 29.19 | ||
| 52-Week Range ($) | 0.696534 - 1.61 | ||
| Shares Outstanding (Mil) | 62.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CytoSorbents Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CytoSorbents Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
CytoSorbents Corp Frequently Asked Questions
What is CytoSorbents Corp(CTSO)'s stock price today?
The current price of CTSO is $1.14. The 52 week high of CTSO is $1.61 and 52 week low is $0.70.
When is next earnings date of CytoSorbents Corp(CTSO)?
The next earnings date of CytoSorbents Corp(CTSO) is 2025-05-09 Est..
Does CytoSorbents Corp(CTSO) pay dividends? If so, how much?
CytoSorbents Corp(CTSO) does not pay dividend.
Guru Commentaries on NAS:CTSO
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers